platinum has been researched along with losartan potassium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degos, L; Demetri, GD; Dicato, M; Glaspy, J | 1 |
| Glaspy, J; Poulsen, E; Rossi, G; Vansteenkiste, J | 1 |
| Giaccone, G; Honkoop, AH; Savonije, JH; van Bochove, A; van Felius, CL; van Groeningen, CJ; Wormhoudt, LW | 1 |
3 trial(s) available for platinum and losartan potassium
| Article | Year |
|---|---|
Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
Topics: Anemia; Blood Transfusion; Disease Progression; Dose-Response Relationship, Drug; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hematinics; Hematologic Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Neoplasms; Platinum; Predictive Value of Tests; Prognosis; Quality of Life; Recombinant Proteins; Retrospective Studies; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2002 |
Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Double-Blind Method; Drug Administration Schedule; Erythrocyte Transfusion; Erythropoietin; Female; Hemoglobins; Humans; Lung Neoplasms; Lymphoproliferative Disorders; Male; Middle Aged; Platinum; Population Surveillance; Sex Factors; Treatment Outcome | 2002 |
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Humans; Male; Middle Aged; Neoplasms; Platinum; Quality of Life; Recombinant Proteins; Survival Analysis | 2005 |